Significados de invasive bladder en inglés

Oncofetal protein expression correlates with the clinical outcome of nonmuscle invasive bladder urothelial carcinoma.

Methods: Nine patients receiving radiotherapy for localized muscle invasive bladder cancer were prospectively studied.

TXAS was among the genes we identified based on its overexpression in invasive bladder tumors.

Nd:YAG laser use in invasive bladder cancer would appear to be adequate for palliation only.

Preliminary studies have shown their safety and efficacy as neoadjuvant therapy in muscle- invasive bladder cancer.

It was performed as a part of multidisciplinary treatment in patients with invasive bladder cancer.

Both TP53 alteration and SFRP gene methylation showed significant independent associations with invasive bladder cancer.

The oncological criterion was organ confined invasive bladder cancer.

We report a comprehensive analysis of 412 muscle- invasive bladder cancers characterized by multiple TCGA analytical platforms.

Objectives: The treatment of non muscle invasive bladder cancer (NMIBC) continues to be a challenge.

Following definitive therapy for muscle invasive bladder cancer, patients remain at risk for local and distant recurrence.

Apaziquone is being studied in two late-stage clinical trials as a treatment for non-muscle invasive bladder cancer.

VI-RADS standardizes reporting of MRI staging and classifies the likelihood of muscle- invasive bladder cancer into five categories.

Purpose: To evaluate bladder preservation protocol by radical TUR-Bt and subsequent concurrent chemoradiotherapy in muscle invasive bladder cancer.

Patient summary: Non-muscle- invasive bladder cancer is a highly recurrent disease that often requires patients to undergo repeated surgical treatments.

Purpose: Radical cystectomy is the gold standard for nonmetastatic muscle invasive bladder cancer and for refractory nonmuscle invasive disease.